The layoffs will not spare Generation’s R&D team, which will initially be retained while the biotech completes its strategic ...

Insmed's Brinsupri is the first DPP1 inhibitor approved by the FDA and the first treatment for bronchiectasis to reach the ...

CBER Chief Vinay Prasad reclaimed his job less than two weeks after his mysterious exit; MAHA implementor Gray Delany is out ...

In May 2025, the White House announced a ‘Most Favored Nation’ approach for setting prescription drug prices. The order aims ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

Jefferies analysts said these detailed safety outcomes confirm the gene therapy's positive risk/benefit profile in ambulatory ...

What if loyalty is holding you back? While it’s a sign of character, consistency and belief in a mission bigger than yourself ...

After a slow 2024, the biotech shell company Concentra Biosciences is back, offering to buy four biotechs in the past month ...

Fred Roeder is a health economist and managing director of the Consumer Choice Center. He has worked in healthcare reform in ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...

For $1.3 billion in aggregate—including upfront and milestone payments—Bayer will get exclusive global access to Kumquat ...

Sarepta’s troubles had nothing to do with Arrowhead’s assets, and yet both companies have seen their stock prices decline ...